Literature DB >> 15216467

Suppression of drug-resistant Staphylococcal Infections by the quorum-sensing inhibitor RNAIII-inhibiting peptide.

Giorgio Dell'Acqua1, Andrea Giacometti, Oscar Cirioni, Roberto Ghiselli, Vittorio Saba, Giorgio Scalise, Yael Gov, Naomi Balaban.   

Abstract

Staphylococcus aureus and S. epidermidis are major causes of infection related to biofilm formed on indwelling medical devices. Such infections are common causes of morbidity and mortality and, because of biofilm resistance to antibiotics, are difficult to treat. The RNAIII-inhibiting peptide (RIP) (YSPWTNF-NH2) inhibits the pathogenesis of staphylococci by disrupting bacterial cell-cell communication (known as "quorum sensing"). Using a vascular-graft rat model, we show that RIP, applied locally and systemically, can completely inhibit drug-resistant S. aureus and S. epidermidis biofilms. The present study provides the first direct demonstration that interfering with cell-cell communication by use of a quorum-sensing inhibitor can eliminate medical device-associated staphylococcal infections. We suggest that medical devices could be coated with RIP to prevent infections, including those by antibiotic-resistant staphylococcal strains.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15216467     DOI: 10.1086/386546

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Adjunctive therapies in the treatment of osteomyelitis.

Authors:  Robert C Fang; Robert D Galiano
Journal:  Semin Plast Surg       Date:  2009-05       Impact factor: 2.314

2.  Quorum sensing inhibitors of Staphylococcus aureus from Italian medicinal plants.

Authors:  Cassandra L Quave; Lisa R W Plano; Bradley C Bennett
Journal:  Planta Med       Date:  2010-07-19       Impact factor: 3.352

3.  Transcriptional profiling of target of RNAIII-activating protein, a master regulator of staphylococcal virulence.

Authors:  Moshe Korem; Yael Gov; Madanahally D Kiran; Naomi Balaban
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

Review 4.  Prevention of catheter-associated urinary tract infection.

Authors:  Barbara W Trautner; Richard A Hull; Rabih O Darouiche
Journal:  Curr Opin Infect Dis       Date:  2005-02       Impact factor: 4.915

5.  Treatment of Staphylococcus aureus biofilm infection by the quorum-sensing inhibitor RIP.

Authors:  Naomi Balaban; Oscar Cirioni; Andrea Giacometti; Roberto Ghiselli; Joel B Braunstein; Carmela Silvestri; Federico Mocchegiani; Vittorio Saba; Giorgio Scalise
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

6.  Mutation of traP in Staphylococcus aureus has no impact on expression of agr or biofilm formation.

Authors:  Laura H Tsang; Sonja T Daily; Elizabeth C Weiss; Mark S Smeltzer
Journal:  Infect Immun       Date:  2007-06-04       Impact factor: 3.441

7.  Controlling bacterial behavior with indole-containing natural products and derivatives.

Authors:  Roberta J Melander; Marine J Minvielle; Christian Melander
Journal:  Tetrahedron       Date:  2014-09-16       Impact factor: 2.457

8.  Siamycin attenuates fsr quorum sensing mediated by a gelatinase biosynthesis-activating pheromone in Enterococcus faecalis.

Authors:  Jiro Nakayama; Emi Tanaka; Reiko Kariyama; Koji Nagata; Kenzo Nishiguchi; Ritsuko Mitsuhata; Yumi Uemura; Masaru Tanokura; Hiromi Kumon; Kenji Sonomoto
Journal:  J Bacteriol       Date:  2006-10-27       Impact factor: 3.490

9.  Attenuation of Edwardsiella tarda virulence by small peptides that interfere with LuxS/autoinducer type 2 quorum sensing.

Authors:  Min Zhang; Xu-dong Jiao; Yong-hua Hu; Li Sun
Journal:  Appl Environ Microbiol       Date:  2009-05-01       Impact factor: 4.792

10.  Inactivation of traP has no effect on the agr quorum-sensing system or virulence of Staphylococcus aureus.

Authors:  Lindsey N Shaw; Ing-Marie Jonsson; Vineet K Singh; Andrej Tarkowski; George C Stewart
Journal:  Infect Immun       Date:  2007-06-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.